Patents by Inventor Kavitha Yaddanapudi

Kavitha Yaddanapudi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240091329
    Abstract: Provided are compositions, optionally pharmaceutical compositions, that include a plurality of exosomes generated from stem cells, optionally ESCs and/or iPSCs, that have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a human GM-CSF polypeptide. Also provided are methods for employing the presently disclosed compositions for preventing and/or inhibiting tumor growth in subjects in need thereof, for preventing and/or inhibiting metastases in subject in need thereof, for inducing anti-tumor immune responses in subjects, and uses of the presently disclosed compositions for prevention and/or treatment of tumors and/or cancers and for the preparation of medicaments for treatment of tumors and/or cancers.
    Type: Application
    Filed: June 12, 2023
    Publication date: March 21, 2024
    Applicant: University of Louisville Research Foundation, Inc.
    Inventors: John W Eaton, Kavitha Yaddanapudi, Chi Li
  • Patent number: 11672849
    Abstract: Provided are compositions, optionally pharmaceutical compositions, that include a plurality of exosomes generated from stem cells, optionally ESCs and/or iPSCs, that have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a human GM-CSF polypeptide. Also provided are methods for employing the presently disclosed compositions for preventing and/or inhibiting tumor growth in subjects in need thereof, for preventing and/or inhibiting metastases in subject in need thereof, for inducing anti-tumor immune responses in subjects, and uses of the presently disclosed compositions for prevention and/or treatment of tumors and/or cancers and for the preparation of medicaments for treatment of tumors and/or cancers.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 13, 2023
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: John W. Eaton, Kavitha Yaddanapudi, Chi Li
  • Publication number: 20210060148
    Abstract: Provided are compositions, optionally pharmaceutical compositions, that include a plurality of exosomes generated from stem cells, optionally ESCs and/or iPSCs, that have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a human GM-CSF polypeptide. Also provided are methods for employing the presently disclosed compositions for preventing and/or inhibiting tumor growth in subjects in need thereof, for preventing and/or inhibiting metastases in subject in need thereof, for inducing anti-tumor immune responses in subjects, and uses of the presently disclosed compositions for prevention and/or treatment of tumors and/or cancers and for the preparation of medicaments for treatment of tumors and/or cancers.
    Type: Application
    Filed: May 9, 2018
    Publication date: March 4, 2021
    Applicant: University of Louisville Research Foundation, Inc.
    Inventors: John W. Eaton, Kavitha Yaddanapudi, Chi Li
  • Publication number: 20190343935
    Abstract: This disclosure provides for methods of treating tumors.
    Type: Application
    Filed: March 10, 2017
    Publication date: November 14, 2019
    Inventors: John W. Eaton, Kavitha Yaddanapudi
  • Publication number: 20180147198
    Abstract: Provided herein is a method of treating cancer and stimulating anti-tumor immunity in a subject in need thereof, the method including administering to the subject a synergistic, therapeutically effective amount of a PFKFB3 inhibitor, such as PFK-158, in combination with an immune checkpoint inhibitor. Also provided is a method of synergistically increasing activity of an immune checkpoint inhibitor, the method including administering to a subject in need thereof a combination therapy including PFK-158 and the immune checkpoint inhibitor. A pharmaceutical composition including PFK-158, at least one immune checkpoint inhibitor; and at least one pharmaceutically-acceptable carrier is also provided.
    Type: Application
    Filed: May 27, 2016
    Publication date: May 31, 2018
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Jason CHESNEY, Sucheta TELANG, Kavitha YADDANAPUDI
  • Publication number: 20150183834
    Abstract: The invention provides a region of strong secondary structure conservation between the C-terminus domain of the envelope glycoprotein of filoviruses and an immunosuppressive domain found in retroviral envelope glycoproteins. The invention provides filoviral peptides and modified derivatives thereof with strong immunosuppressive bioactivity. The invention further provides methods for treatment of autoimmune disorders by administering the immunosuppressive peptide. The invention also provides methods for the identification of therapeutic agents that modulate the immunosuppressive activity of the peptides. Antibodies against the inventive peptides and the modified derivatives thereof are also provided. Furthermore, the invention provides methods for treatment of filoviral infection by administering compositions comprising the antibodies and/or the therapeutic agents that modulate the immunosuppressive activity of the inventive peptides.
    Type: Application
    Filed: April 30, 2014
    Publication date: July 2, 2015
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: W. Ian LIPKIN, Kavitha YADDANAPUDI, Gustavo PALACIOS
  • Publication number: 20070185025
    Abstract: The invention provides a region of strong secondary structure conservation between the C-terminus domain of the envelope glycoprotein of filoviruses and an immunosuppressive domain found in retroviral envelope glycoproteins. The invention provides filoviral peptides and modified derivatives thereof with strong immunosuppressive bioactivity. The invention further provides methods for treatment of autoimmune disorders by administering the immunosuppressive peptide. The invention also provides methods for the identification of therapeutic agents that modulate the immunosuppressive activity of the peptides. Antibodies against the inventive peptides and the modified derivatives thereof are also provided. Furthermore, the invention provides methods for treatment of filoviral infection by administering compositions comprising the antibodies and/or the therapeutic agents that modulate the immunosuppressive activity of the inventive peptides.
    Type: Application
    Filed: September 11, 2006
    Publication date: August 9, 2007
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Gustavo Palacios, Kavitha Yaddanapudi, W. Lipkin